CYPHERPUNK TECHNOLOGIES INC. Deferred Revenue Recognized
CYPHERPUNK TECHNOLOGIES INC. (CYPH) reported Deferred Revenue Recognized of $1.50 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-12.
Discontinued › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2021-03-12
- CYPHERPUNK TECHNOLOGIES INC. contract with customer, liability, revenue recognized for fiscal 2020 was $1.50M.
| Period end | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|
| 2020-12-31 | $1.50M 10-K · filed 2021-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |